Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
- This clinical trial proposal is based on the FDA protocol for emergency use of
convalescent plasma for treatment of COVID-19 cases, and on the WHO guidelines for use
of convalescent plasma in other infectious diseases.
- This Clinical trial is to be applied in Cairo University quarantine hospital. The
collection, testing and storage of convalescent plasma will be done inside CUH main
blood bank.
The concept of this clinical trial is built on the collection of convalescent plasma from
individuals who had recovered from documented infection with SARS-CoV-2, to be used for
patients with- or at high risk of progression to- severe/life-threatening clinical conditions
due to SARS-CoV-2 infection.
An informed consent is required to join this clinical trial; patients will be transfused with
one or two units of ABO compatible convalescent plasma. Those patients will be followed up
and the clinical and laboratory data will be compiled, including adverse events related to
the administration of convalescent plasma (CP).
Other data to be collected retrospectively will include patient demographics, acute care
facility resource utilization (total length of stay, days in ICU, days intubated, and
survival till discharge from an acute care facility).